For localized information and support, would you like to switch to your country-specific website for {0}?
cobas® EBV

Setting a new standard for transplant patients
The cobas® EBV test provides reliable, standardized, high-quality results for the improved management of transplant patients at risk of infection. The test is intended as an aid in the diagnosis and management of Epstein-Barr Virus (EBV) in transplant patients, with results used to guide treatment decisions.2 The test is for use on the automated cobas® 5800/6800/8800 systems.
Epstein-Barr virus
Epstein-Barr Virus (EBV) diseases, including EBV-associated post-transplant lymphoproliferative disorder (PTLD), remain important causes of morbidity and mortality in patients undergoing solid organ transplantation and hematopoietic cell transplantation.1 Early detection with best-in-class monitoring tools provides actionable results, which enable informed treatment decisions.
cobas EBV test for cobas 5800/6800/8800 systems performance2
View full tablecobas EBV test for cobas 5800/6800/8800 systems performance2
Product specification |
Value |
Sample type |
EDTA plasma |
Minimum amount of sample required |
350 µL |
Sample processing volume |
200 µL |
Analytical sensitivity |
18.8 IU/mL |
Linear range |
35.0 IU/mL to 1E+08 IU/mL |
Genotypes detected |
Genotypes 1 and 2 |
Overall precision |
SD 0.02 - 0.17 log10 |
Related products
References
- Allen UD, Preiksaitis JK, AST Infectious Diseases Community of Practice. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13652.
- F. Hoffmann-La Roche Ltd. cobas® EBV quantitative nucleic acid test for use on cobas® 5800/6800/8800 systems. Package insert (09478116001-04EN). (v4.0). 2024.